ClinicalTrials.gg
CompletedNCT04539262Updated Mar 3, 2022Results posted

Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation

A Phase 1/2 interventional study of Remdesivir (RDV) and Placebo in COVID-19, sponsored by Gilead Sciences. Completed at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-03.

Sponsored by Gilead Sciences · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing remdesivir in COVID-19 — 6 open to participants now, 9 under way, 3 of them phase 3. remdesivir · COVID-19.

Enrollment
27th of 40
156 · median 283
Started
2020
with 26 others
Phase 1/2
Only one
of the 40
Registered
19th of 40
by date
Lead sponsor
6 of 40
Gilead Sciences

Among the 40 studies testing remdesivir in COVID-19, this one is the 27th largest by enrollment, is one of 27 that started in 2020, is the only one in phase 1/2, and was the 19th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 40 studies testing remdesivir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About remdesivir

remdesivir: first FDA approval 2020 (VEKLURY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing remdesivir in COVID-19, or all of them as a file.
02

Study summary

The primary objective of this study is to characterize the impact of inhaled remdesivir (RDV) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in participants with early stage coronavirus disease 2019 (COVID-19).

Read the detailed description

This study will have multiple parts: Part A, Part B, and Part C. Part B will be conducted if supported by evaluation in healthy volunteers in another Phase 1a Gilead study (GS-US-553-9018). Participants in Part C will be enrolled after review of preliminary safety and available efficacy data from Parts A and B through at least Day 7.

GS-US-553-9018 is a Phase 1a randomized, blinded, placebo-controlled, single- and multiple-dose study in healthy volunteers to evaluate the safety, tolerability, and pharmacokinetics of remdesivir administered by inhalation.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Willing and able to provide written , or with a legal representative who can provide informed consent
  • SARS-CoV-2 infection first confirmed by polymerase chain reaction (PCR) (Parts A and B) or by nucleic acid testing or direct antigen testing (Part C) with sample collected ≤ 4 days prior to randomization
  • COVID-19 symptom onset ≤ 7 days prior to randomization
  • Oxygen saturation as measured by pulse oximetry (SpO2) > 94% on room air

Key Exclusion Criteria:

  • Ongoing or prior participation in any other clinical trial of an experimental vaccine or treatment for COVID-19
  • Prior or current hospitalization for COVID-19 or need for hospitalization
  • Treatment of COVID-19 with other agents with actual or possible direct antiviral activity against SARS-CoV-2 including intravenous (IV) RDV or administration of any SARS-CoV-2 (or COVID-19) vaccine

    • Participants chronically administered chloroquine or hydroxychloroquine for any reason are to be excluded
  • Requiring oxygen supplementation
  • Positive pregnancy test
  • Breastfeeding female
  • Known to the study treatment, its metabolites, or formulation
  • Pre-existing pulmonary conditions such as or asthma (Parts A and B only)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    Remdesivir (RDV), Part A

    Participants will receive inhaled RDV 31 mg administered daily for 5 days.

    Drug: Remdesivir (RDV)

  • Experimental
    RDV + Placebo, Part A

    Participants will receive inhaled RDV 31 mg administered daily for 3 days followed by placebo to match RDV daily for 2 days.

    Drug: Remdesivir (RDV) · Drug: Placebo

  • Placebo comparator
    Placebo, Part A

    Participants will receive placebo to match inhaled RDV in Part A daily for 5 days.

    Drug: Placebo

  • Experimental
    RDV, Part B

    Participants will receive inhaled RDV 62 mg administered daily for up to 5 days.

    Drug: Remdesivir (RDV)

  • Experimental
    RDV + Placebo, Part B

    Participants will receive inhaled RDV 62 mg administered daily for up to 3 days followed by placebo to match RDV daily for 2 days.

    Drug: Remdesivir (RDV) · Drug: Placebo

  • Placebo comparator
    Placebo, Part B

    Participants will receive placebo to match inhaled RDV in Part B daily for 5 days.

    Drug: Placebo

  • Experimental
    RDV, Part C

    Participants will receive inhaled RDV 39 mg administered daily for 5 days.

    Drug: Remdesivir (RDV)

  • Placebo comparator
    Placebo, Part C

    Participants will receive placebo to match inhaled RDV in Part C daily for 5 days.

    Drug: Placebo

Interventions

  • Administered as an aerosolized solution

    Also known as: GS-5734™

  • DrugPlacebo

    Administered as an aerosolized solution

06

What researchers measure

Primary outcomes

  1. Time-weighted Average Change From Baseline in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7

    Time-weighted average change in SARS-CoV-2 viral load was defined as area under the concentration versus time curve (AUC) of viral load change divided by time between baseline through Day 7.

    Time frame: Baseline, Day 7

  2. Time-weighted Average Change From Baseline in Oropharyngeal SARS-CoV-2 Viral Load Through Day 7

    Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.

    Time frame: Baseline, Day 7

  3. Time-weighted Average Change From Baseline in Saliva SARS-CoV-2 Viral Load Through Day 7

    Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.

    Time frame: Baseline, Day 7

Secondary outcomes

  1. Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant administered a study drug, which did not necessarily have a causal relationship with the treatment. AE was therefore any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug. TEAEs: AE with an onset date on or after the study drug start date and no later than 30 days after study drug stop date; or any AE leading to study drug discontinuation.

    Time frame: First dose date up to 5 days plus 30 days

  2. Percentage of Participants With Treatment-Emergent Laboratory Abnormalities as Per Severity Grade

    Treatment-emergent laboratory abnormalities were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 July 2017. Laboratory abnormalities were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening). Percentage of participants with any severity grade were reported.

    Time frame: First dose date up to 5 days plus 30 days

  3. Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation

    Time frame: First dose date up to 5 days plus 30 days

  4. Number of Participants With All-Cause Medically Attended Visits (MAVs) or Death by Day 28

    The composite outcome of all-cause MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.

    Time frame: Randomization up to Day 28

  5. Number of Participants With COVID-19 Related MAVs or Death by Day 28

    The composite outcome of COVID-19 related MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.

    Time frame: Randomization up to Day 28

  6. Number of Participants With Hospitalization by Day 28

    The composite of all-cause hospitalization was estimated using Kaplan-Meier methods by treatment group.

    Time frame: Day 1 up to Day 28

  7. Pharmacokinetic (PK) Parameter: AUC0-24h of Remdesivir (RDV) and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

    AUC0-24h was defined as the concentration of drug over time between time 0 to time 24 hours. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

    Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

  8. PK Parameter: AUClast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

    AUClast was defined as the concentration of drug from time zero to the last observable concentration.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

    Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

  9. PK Parameter: CLss/F of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

    CLss/F was defined as apparent oral clearance at steady state after administration of the drug. CLss/F = Dose/AUCtau, where "Dose" is the dose of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

    Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

  10. PK Parameter: t1/2 of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

    t1/2 was defined as the estimate of the terminal elimination half-life of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

    Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

  11. PK Parameter: Vz/F of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

    Vz/F was defined as the apparent volume of distribution of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

    Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

  12. PK Parameter: Cmax of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

    Cmax was defined as the maximum observed concentration of drug.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

    Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

  13. PK Parameter: Tmax of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

    Tmax was defined as the time (observed time point) of Cmax. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

    Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

  14. PK Parameter: Clast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

    Clast was defined as the last observable concentration of drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

    Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

  15. PK Parameter: Tlast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

    Tlast was defined as the time (observed time point) of Clast. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

    Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

  16. PK Parameter: AUCtau of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

    AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval). Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

    Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

  17. PK Parameter: λz of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

    λz was defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

    Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

  18. PK Parameter: Ctau of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

    Ctau was defined as the observed drug concentration at the end of the dosing interval. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

    Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

  19. Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5

    Time frame: Baseline, Day 5

  20. Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5

    Time frame: Baseline, Day 5

  21. Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 5

    Time frame: Baseline, Day 5

  22. Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7

    Time frame: Baseline, Day 7

  23. Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7

    Time frame: Baseline, Day 7

  24. Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 7

    Time frame: Baseline, Day 7

  25. Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B

    Time frame: Baseline, Day 14

  26. Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B

    Time frame: Baseline, Day 14

  27. Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B

    Time frame: Baseline, Day 14

  28. Time to Negative Nasopharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)

    The time to negative nasopharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using nasopharyngeal sample. Time to negative nasopharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.

    Time frame: Baseline up to Day 17

  29. Time to Negative Oropharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)

    The time to negative oropharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using an oropharyngeal sample. Time to negative oropharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.

    Time frame: Baseline up to Day 17

  30. Time to Negative Saliva SARS-CoV-2 Polymerase Chain Reaction (PCR)

    The time to saliva SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using saliva sample. Time to negative saliva SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.

    Time frame: Baseline up to Day 17

  31. Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19 Adapted InFLUenza Patient-Reported Outcome (FLU-PRO©) Questionnaire in Part C

    The InFLUenza Patient-Reported Outcome (FLU-PRO©) is a 32-item patient-reported outcome questionnaire that assesses the severity of symptoms of influenza and influenza-like illness across six body systems. An additional two items can be added to assess changes in taste or smell, if the instrument is used to quantify symptoms in studies of COVID-19. Each domain scores ranges from 0 (symptom-free) to 4 (very severe symptoms). Higher scores on this scale represent higher disease severity. Alleviation is defined as symptom scores as 2 or higher at baseline are scored as 0 (absent) or 1 (mild) at post-baseline, and symptoms scored as 1 at baseline are scored as 0 at post-baseline, and for two consecutive days. Time to alleviation was calculated using Kaplan-Meier estimates.

    Time frame: First dose date up to Day 14

07

Results

Posted Mar 3, 2022

Participant flow

Participants were enrolled at study sites in the United States. The first participant was screened on 14 September 2020. The last study visit occurred on 22 March 2021.

Participant flow — Overall Study
MilestoneRemdesivir (RDV), Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Started1213121212136220
Completed1212111112136120
Not completed01110010
Withdrew: Adverse event00100000
Withdrew: Withdrew consent00010000
Withdrew: Randomized, not treated01000010

Outcome measures

PrimaryTime-weighted Average Change From Baseline in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7

Time-weighted average change in SARS-CoV-2 viral load was defined as area under the concentration versus time curve (AUC) of viral load change divided by time between baseline through Day 7.

Time frame:
Baseline, Day 7
Reported as:
Mean · log10 copies/mL
Time-weighted Average Change From Baseline in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7
log10 copies/mLRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Time-weighted Average Change From Baseline in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7-2.04 ± 0.999-1.51 ± 0.812-1.24 ± 0.961-1.21 ± 1.108-1.42 ± 0.975-1.40 ± 0.796-1.91 ± 1.186-1.93 ± 1.284
Statistical analysis
  • RDV, Part A vs Placebo, Part A · ANCOVA · p = 0.1117 (Least square (LS) Mean, Standard Error (SE), 95% CI and p-value were from Analysis of covariance (ANCOVA) with baseline viral load as a covariate.) · Least square mean difference by day 7: -0.66 · 95% CI -1.49 to 0.16
  • RDV + Placebo, Part A vs Placebo, Part A · ANCOVA · p = 0.3793 (LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.) · Ls mean difference by day 7: -0.35 · 95% CI -1.16 to 0.46
  • RDV, Part B vs Placebo, Part B · ANCOVA · p = 0.5248 (LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate) · Ls mean difference by day 7: -0.24 · 95% CI -1.00 to 0.52
  • RDV + Placebo, Part B vs Placebo, Part B · ANCOVA · p = 0.4610 · Ls mean difference by day 7: -0.25 · 95% CI -0.94 to 0.44LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate
  • RDV, Part C vs Placebo, Part C · ANCOVA · p = 0.5006 (LS Mean (SE), 95% CI and p-value were from ANCOVA with baseline viral load as a covariate.) · Ls mean difference by day 7: 0.20 · 95% CI -0.40 to 0.81
PrimaryTime-weighted Average Change From Baseline in Oropharyngeal SARS-CoV-2 Viral Load Through Day 7

Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.

Time frame:
Baseline, Day 7
Reported as:
Mean · log10 copies/mL
Time-weighted Average Change From Baseline in Oropharyngeal SARS-CoV-2 Viral Load Through Day 7
log10 copies/mLRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Time-weighted Average Change From Baseline in Oropharyngeal SARS-CoV-2 Viral Load Through Day 7-1.10 ± 0.856-0.55 ± 0.868-1.39 ± 1.036-1.14 ± 1.133-0.85 ± 1.164-0.70 ± 0.902-0.83 ± 1.073-0.46 ± 1.152
Statistical analysis
  • RDV, Part A vs Placebo, Part A · ANCOVA · p = 0.3417 (LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.) · Ls mean difference by day 7: 0.33 · 95% CI -0.37 to 1.02
  • RDV + Placebo, Part A vs Placebo, Part A · ANCOVA · p = 0.1803 (LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.) · Ls mean difference by day 7: 0.49 · 95% CI -0.24 to 1.21
  • RDV, Part B vs Placebo, Part B · ANCOVA · p = 0.1233 (LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.) · Ls mean difference by day 7: -0.55 · 95% CI -1.27 to 0.16
  • RDV + Placebo, Part B vs Placebo, Part B · ANCOVA · p = 0.8203 (LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.) · Ls mean difference by day 7: 0.08 · 95% CI -0.64 to 0.80
  • RDV, Part C vs Placebo, Part C · ANCOVA · p = 0.6458 (LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.) · Ls mean difference by day 7: -0.12 · 95% CI -0.65 to 0.41
PrimaryTime-weighted Average Change From Baseline in Saliva SARS-CoV-2 Viral Load Through Day 7

Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.

Time frame:
Baseline, Day 7
Reported as:
Mean · log10 copies/mL
Time-weighted Average Change From Baseline in Saliva SARS-CoV-2 Viral Load Through Day 7
log10 copies/mLRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Time-weighted Average Change From Baseline in Saliva SARS-CoV-2 Viral Load Through Day 7-0.80 ± 0.469-1.27 ± 0.877-0.49 ± 1.148-1.09 ± 1.497-0.61 ± 0.676-0.93 ± 0.678-1.25 ± 0.977-1.01 ± 1.096
Statistical analysis
  • RDV, Part A vs Placebo, Part A · ANCOVA · p = 0.5951 (LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.) · Ls mean difference by day 7: -0.22 · 95% CI -1.05 to 0.61
  • RDV + Placebo, Part A vs Placebo, Part A · ANCOVA · p = 0.0872 · Ls mean difference by day 7: -0.71 · 95% CI -1.54 to 0.11
  • RDV, Part B vs Placebo, Part B · ANCOVA · p = 0.6031 (LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.) · Ls mean difference by day 7: -0.19 · 95% CI -0.94 to 0.56
  • RDV + Placebo, Part B vs Placebo, Part B · ANCOVA · p = 0.7578 (LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.) · Ls mean difference by day 7: 0.12 · 95% CI -0.64 to 0.87
  • RDV, Part C vs Placebo, Part C · ANCOVA · p = 0.8846 (LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.) · Ls mean difference by day 7: 0.04 · 95% CI -0.48 to 0.56
SecondaryPercentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant administered a study drug, which did not necessarily have a causal relationship with the treatment. AE was therefore any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug. TEAEs: AE with an onset date on or after the study drug start date and no later than 30 days after study drug stop date; or any AE leading to study drug discontinuation.

Time frame:
First dose date up to 5 days plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
percentage of participantsRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)58.358.341.733.358.338.542.625.0
SecondaryPercentage of Participants With Treatment-Emergent Laboratory Abnormalities as Per Severity Grade

Treatment-emergent laboratory abnormalities were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 July 2017. Laboratory abnormalities were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening). Percentage of participants with any severity grade were reported.

Time frame:
First dose date up to 5 days plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Laboratory Abnormalities as Per Severity Grade
percentage of participantsRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Percentage of Participants With Treatment-Emergent Laboratory Abnormalities as Per Severity Grade58.391.763.663.683.361.568.975.0
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation
Time frame:
First dose date up to 5 days plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation
percentage of participantsRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation008.30001.60
SecondaryNumber of Participants With All-Cause Medically Attended Visits (MAVs) or Death by Day 28

The composite outcome of all-cause MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.

Time frame:
Randomization up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With All-Cause Medically Attended Visits (MAVs) or Death by Day 28
ParticipantsRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Number of Participants With All-Cause Medically Attended Visits (MAVs) or Death by Day 2811101100
SecondaryNumber of Participants With COVID-19 Related MAVs or Death by Day 28

The composite outcome of COVID-19 related MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.

Time frame:
Randomization up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With COVID-19 Related MAVs or Death by Day 28
ParticipantsRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Number of Participants With COVID-19 Related MAVs or Death by Day 2801100100
SecondaryNumber of Participants With Hospitalization by Day 28

The composite of all-cause hospitalization was estimated using Kaplan-Meier methods by treatment group.

Time frame:
Day 1 up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Hospitalization by Day 28
ParticipantsRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Number of Participants With Hospitalization by Day 2801101100
SecondaryPharmacokinetic (PK) Parameter: AUC0-24h of Remdesivir (RDV) and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

AUC0-24h was defined as the concentration of drug over time between time 0 to time 24 hours. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

Time frame:
Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

No measurements were reported for this outcome.

SecondaryPK Parameter: AUClast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

AUClast was defined as the concentration of drug from time zero to the last observable concentration.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

Time frame:
Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

No measurements were reported for this outcome.

SecondaryPK Parameter: CLss/F of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

CLss/F was defined as apparent oral clearance at steady state after administration of the drug. CLss/F = Dose/AUCtau, where "Dose" is the dose of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

Time frame:
Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

No measurements were reported for this outcome.

SecondaryPK Parameter: t1/2 of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

t1/2 was defined as the estimate of the terminal elimination half-life of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

Time frame:
Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

No measurements were reported for this outcome.

SecondaryPK Parameter: Vz/F of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

Vz/F was defined as the apparent volume of distribution of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

Time frame:
Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

No measurements were reported for this outcome.

SecondaryPK Parameter: Cmax of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

Cmax was defined as the maximum observed concentration of drug.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

Time frame:
Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

No measurements were reported for this outcome.

SecondaryPK Parameter: Tmax of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

Tmax was defined as the time (observed time point) of Cmax. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

Time frame:
Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

No measurements were reported for this outcome.

SecondaryPK Parameter: Clast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

Clast was defined as the last observable concentration of drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

Time frame:
Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

No measurements were reported for this outcome.

SecondaryPK Parameter: Tlast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

Tlast was defined as the time (observed time point) of Clast. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

Time frame:
Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

No measurements were reported for this outcome.

SecondaryPK Parameter: AUCtau of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval). Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

Time frame:
Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

No measurements were reported for this outcome.

SecondaryPK Parameter: λz of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

λz was defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

Time frame:
Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

No measurements were reported for this outcome.

SecondaryPK Parameter: Ctau of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B

Ctau was defined as the observed drug concentration at the end of the dosing interval. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.

Time frame:
Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.

No measurements were reported for this outcome.

SecondaryChange in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5
Time frame:
Baseline, Day 5
Reported as:
Mean · log10 copies/mL
Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5
log10 copies/mLRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5-2.44 ± 1.240-1.67 ± 0.992-1.78 ± 1.357-1.53 ± 1.063-1.68 ± 1.475-2.09 ± 1.052-2.01 ± 1.402-2.06 ± 1.321
SecondaryChange in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5
Time frame:
Baseline, Day 5
Reported as:
Mean · log10 copies/mL
Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5
log10 copies/mLRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5-1.24 ± 0.957-0.88 ± 0.839-1.26 ± 1.418-1.29 ± 1.457-1.13 ± 1.394-1.10 ± 0.988-0.92 ± 1.213-0.66 ± 1.581
SecondaryChange in Saliva SARS-CoV-2 Viral Load From Baseline to Day 5
Time frame:
Baseline, Day 5
Reported as:
Mean · log10 copies/mL
Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 5
log10 copies/mLRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 5-0.99 ± 0.562-1.26 ± 1.288-0.77 ± 1.449-1.60 ± 1.443-0.31 ± 0.708-0.92 ± 1.040-1.36 ± 1.056-1.15 ± 0.962
SecondaryChange in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7
Time frame:
Baseline, Day 7
Reported as:
Mean · log10 copies/mL
Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7
log10 copies/mLRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7-3.05 ± 1.225-2.12 ± 1.051-2.09 ± 1.331-1.80 ± 1.389-2.30 ± 1.257-2.34 ± 1.873-2.64 ± 1.299-2.62 ± 1.555
SecondaryChange in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7
Time frame:
Baseline, Day 7
Reported as:
Mean · log10copies/mL
Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7
log10copies/mLRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7-1.76 ± 1.113-0.40 ± 1.049-1.98 ± 0.971-1.73 ± 1.513-1.08 ± 1.160-1.27 ± 0.845-1.07 ± 1.122-0.62 ± 1.606
SecondaryChange in Saliva SARS-CoV-2 Viral Load From Baseline to Day 7
Time frame:
Baseline, Day 7
Reported as:
Mean · log10 copies/mL
Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 7
log10 copies/mLRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 7-1.28 ± 1.102-1.24 ± 2.108-0.62 ± 1.406-1.91 ± 1.667-0.99 ± 0.943-1.53 ± 1.553-1.69 ± 1.302-1.31 ± 1.752
SecondaryChange in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B
Time frame:
Baseline, Day 14
Reported as:
Mean · log10 copies/mL
Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B
log10 copies/mLRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part B
Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B-4.11 ± 1.304-2.96 ± 1.475-3.31 ± 1.198-2.82 ± 1.888-2.86 ± 1.837-3.41 ± 1.442
SecondaryChange in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B
Time frame:
Baseline, Day 14
Reported as:
Mean · log10 copies/mL
Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B
log10 copies/mLRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part B
Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B-2.46 ± 0.908-1.47 ± 0.841-2.36 ± 0.951-1.46 ± 1.194-1.95 ± 1.283-2.05 ± 1.092
SecondaryChange in Saliva SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B
Time frame:
Baseline, Day 14
Reported as:
Mean · log10 copies/mL
Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B
log10 copies/mLRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part B
Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B-2.58 ± 1.413-2.27 ± 1.136-1.78 ± 0.618-2.30 ± 1.505-2.11 ± 1.171-3.53 ± 1.253
SecondaryTime to Negative Nasopharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)

The time to negative nasopharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using nasopharyngeal sample. Time to negative nasopharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.

Time frame:
Baseline up to Day 17
Reported as:
Median · days
Time to Negative Nasopharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)
daysRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Time to Negative Nasopharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)NA (NA to NA)17.0 (16.0 to 17.0)NA (NA to NA)16.0 (7.0 to 16.0)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to Negative Oropharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)

The time to negative oropharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using an oropharyngeal sample. Time to negative oropharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.

Time frame:
Baseline up to Day 17
Reported as:
Median · days
Time to Negative Oropharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)
daysRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Time to Negative Oropharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)14.0 (5.0 to 15.0)15.0 (4.0 to 16.0)13.0 (7.0 to NA)5.0 (2.0 to 15.0)NA (NA to NA)14.0 (5.0 to 15.0)NA (NA to NA)NA (NA to NA)
SecondaryTime to Negative Saliva SARS-CoV-2 Polymerase Chain Reaction (PCR)

The time to saliva SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using saliva sample. Time to negative saliva SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.

Time frame:
Baseline up to Day 17
Reported as:
Median · days
Time to Negative Saliva SARS-CoV-2 Polymerase Chain Reaction (PCR)
daysRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Time to Negative Saliva SARS-CoV-2 Polymerase Chain Reaction (PCR)NA (NA to NA)17.0 (13.0 to 17.0)NA (NA to NA)16.0 (7.0 to 16.0)14.0 (3.0 to 15.0)NA (NA to NA)NA (NA to NA)16.0 (7.0 to 16.0)
SecondaryTime to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19 Adapted InFLUenza Patient-Reported Outcome (FLU-PRO©) Questionnaire in Part C

The InFLUenza Patient-Reported Outcome (FLU-PRO©) is a 32-item patient-reported outcome questionnaire that assesses the severity of symptoms of influenza and influenza-like illness across six body systems. An additional two items can be added to assess changes in taste or smell, if the instrument is used to quantify symptoms in studies of COVID-19. Each domain scores ranges from 0 (symptom-free) to 4 (very severe symptoms). Higher scores on this scale represent higher disease severity. Alleviation is defined as symptom scores as 2 or higher at baseline are scored as 0 (absent) or 1 (mild) at post-baseline, and symptoms scored as 1 at baseline are scored as 0 at post-baseline, and for two consecutive days. Time to alleviation was calculated using Kaplan-Meier estimates.

Time frame:
First dose date up to Day 14
Reported as:
Median · days
Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19 Adapted InFLUenza Patient-Reported Outcome (FLU-PRO©) Questionnaire in Part C
daysRDV, Part CPlacebo, Part C
Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19 Adapted InFLUenza Patient-Reported Outcome (FLU-PRO©) Questionnaire in Part CNA (NA to NA)NA (NA to NA)

Adverse events

Collected over Adverse Events: First dose date up to 5 days plus 30 days All-Cause Mortality: Randomization date up to 35 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RDV, Part A0/12 (0%)0/12 (0%)7/12 (58.3%)
RDV + Placebo, Part A0/13 (0%)1/12 (8.3%)7/12 (58.3%)
Placebo, Part A0/12 (0%)2/12 (16.7%)5/12 (41.7%)
RDV, Part B0/12 (0%)0/12 (0%)4/12 (33.3%)
RDV + Placebo, Part B0/12 (0%)1/12 (8.3%)6/12 (50%)
Placebo, Part B0/13 (0%)1/13 (7.7%)5/13 (38.5%)
RDV, Part C0/62 (0%)0/61 (0%)24/61 (39.3%)
Placebo, Part C0/20 (0%)0/20 (0%)5/20 (25%)
Most frequent serious events
Most frequent serious events
EventRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
Acute myocardial infarctionCardiac disorders0/120/121/120/120/120/130/610/20
Incarcerated herniaGeneral disorders0/120/120/120/121/120/130/610/20
Covid-19 pneumoniaInfections and infestations0/121/121/120/120/121/130/610/20
Most frequent other events
Showing 10 of 62
Most frequent other events
EventRDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part C
DizzinessNervous system disorders3/120/120/120/120/120/135/611/20
VomitingGastrointestinal disorders0/122/120/120/120/120/130/610/20
Aspartate aminotransferase increasedInvestigations0/120/122/120/120/120/131/610/20
Lacrimation increasedEye disorders0/120/120/120/120/120/131/612/20
SneezingRespiratory, thoracic and mediastinal disorders0/120/120/120/120/120/132/612/20
CoughRespiratory, thoracic and mediastinal disorders0/121/120/121/121/120/136/611/20
LeukocytosisBlood and lymphatic system disorders0/120/121/120/120/120/130/610/20
NeutropeniaBlood and lymphatic system disorders0/121/120/120/120/120/130/610/20
NeutrophiliaBlood and lymphatic system disorders0/120/121/120/120/121/130/610/20
TinnitusEar and labyrinth disorders0/120/121/120/120/120/130/610/20

Baseline characteristics

The Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study treatment.

Age, Customized
Age, Customized(Participants)RDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part CTotal
< 60 years101191210125515134
≥ 60 years2130216520
Sex: Female, Male
Sex: Female, Male(Participants)RDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part CTotal
Female85475634877
Male478577271277
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part CTotal
Hispanic or Latino633264401478
Not Hispanic or Latino699104921674
Unknown or Not Reported000020002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part CTotal
Race — Asian011000002
Race — Black00001112216
Race — White119101110124716126
Race — American Indian or Alaska Native000000112
Race — Not Permitted121010005
Race — Other000100113
SARS-CoV-2 Viral load - Nasopharyngeal
SARS-CoV-2 Viral load - Nasopharyngeal(log10 copies/mL)RDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part CTotal
Mean7.29 ± 1.9016.56 ± 1.0656.81 ± 1.0655.23 ± 1.9806.41 ± 1.8837.09 ± 1.2885.69 ± 2.0045.76 ± 1.8396.14 ± 1.859
SARS-CoV-2 Viral load - Oropharyngeal
SARS-CoV-2 Viral load - Oropharyngeal(log10 copies/mL)RDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part CTotal
Mean5.69 ± 0.9594.74 ± 1.2255.57 ± 1.2754.40 ± 1.7725.16 ± 1.3564.79 ± 1.3774.38 ± 1.6103.94 ± 1.2034.64 ± 1.505
SARS-CoV-2 Viral load - Saliva
SARS-CoV-2 Viral load - Saliva(log10 copies/mL)RDV, Part ARDV + Placebo, Part APlacebo, Part ARDV, Part BRDV + Placebo, Part BPlacebo, Part BRDV, Part CPlacebo, Part CTotal
Mean5.56 ± 1.6825.19 ± 1.3124.77 ± 1.2185.15 ± 2.0484.77 ± 1.2815.60 ± 1.0744.93 ± 1.7854.57 ± 1.5595.00 ± 1.613
08

Study locations

28 sites
  • The Institute for Liver Health
    Mesa, Arizona 85210, United States
  • The Institute for Liver Health
    Tucson, Arizona 85712, United States
  • Franco Felizarta, MD
    Bakersfield, California 93301, United States
  • Aurora FDRC Inc.
    Costa Mesa, California 92627, United States
  • Elevated Health
    Huntington Beach, California 92648, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Western Clinical Research
    Placentia, California 92870, United States
  • UC Davis Health/Medical Center
    Sacramento, California 95817, United States
  • Bradenton Research Center, Inc.
    Bradenton, Florida 34205, United States
  • Integrity Clinical Research, LLC
    Doral, Florida 33166, United States
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
  • Evolution Clinical Trials, Inc.
    Hialeah Gardens, Florida 33016, United States
  • Research in Miami, Inc.
    Hialeah, Florida 33013, United States
  • Optimus U Corporation
    Miami, Florida 33125, United States
  • L & C Professional Medical Research Institute
    Miami, Florida 33144, United States
  • Westchester Research Center at Westchester General Hospital
    Miami, Florida 33155, United States
  • MedBio Trials
    Miami, Florida 33180, United States
  • Nuovida Research Center, Corp
    Miami, Florida 33186, United States
  • IMIC Inc
    Palmetto Bay, Florida 33157, United States
  • Triple O Research Institute, PA
    West Palm Beach, Florida 33401, United States
  • Family Care Research
    Boise, Idaho 83704, United States
  • CTU Covid Research Center
    New Orleans, Louisiana 70112, United States
  • STAT Research
    Vandalia, Ohio 45066, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • DFW Clinical Research
    Dallas, Texas 75234, United States
  • Baylor Research Institute
    Dallas, Texas 75246, United States
  • PCP for Life-Tidwell
    Houston, Texas 77093, United States
  • Providence Regional Medical Center Everett
    Everett, Washington 98201, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Feb 2021, 5 months.

Results were first posted in Mar 2022, 1 year after primary completion.

Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 5 months is below that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2020
First posted
Sep 4, 2020
StartActual
Sep 14, 2020
Primary completionActual
Feb 26, 2021
CompletionActual
Mar 22, 2021
Results first posted
Mar 3, 2022
Last update
Mar 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04539262
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 4, 2020
Start date
Sep 14, 2020
Primary completion
Feb 26, 2021
Completion
Mar 22, 2021
Results posted
Mar 3, 2022
Last update
Mar 3, 2022

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remdesivir

Start the discussion